Impact of Beta-blocker on Outcome Among Patients Undergoing Transcatheter Aortic Valve Replacement (B-TAVR)
Key facts
- Where
- Graz and Salzburg, AustriaSee the 2 sites
- Phase
- Phase 4
Where in Austria
- Medical University of Graz, Department of Internal Medicine, University Heart Centre GrazGraz, AustriaTaking people
- University Hospital SalzburgSalzburg, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT06472934EU 2024-518731-11-00
- Record updated
- 28 November 2025
- Original description
This is a multi-centric, open-label, randomized trial to evaluate the safety and efficacy of temporary discontinuation of beta-blocker treatment in patients undergoing transcatheter aortic valve replacement.Read full original descriptionShow less
Impact of Beta-blocker Administration on Outcome Among Patients Undergoing Transcatheter Aortic Valve Replacement B-TAVR
This is a multi-centric, open-label, randomized trial to evaluate the safety and efficacy of temporary discontinuation of beta-blocker treatment in patients undergoing transcatheter aortic valve replacement.
Inclusion: Informed Consent must be signed by the subject prior to any study intervention; Adult patients (> 18 years) with severe symptomatic aortic stenosis eligible and scheduled for elective TAVR and are able to give consentand are able to give consent; Indication for B-blocker therapy with a prior treatment duration of at least 1 month before inclusion.
Exclusion: Hemodynamically unstable patients receiving inotropic medication; Prior permanent pacemaker implantation; Prior intolerance of B-blocker medication; Known or suspected non-compliance, drug, or alcohol abuse; Participation in another study with investigational drug within the 30 days preceding and during the present study; Previous enrolment into the current study; Inability to give consent, or follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant; Emergency or urgent indication for TAVR; Existing indication for pacemaker implantation; Hemodynamic relevant left ventricular outflow tract obstruction; Life expectancy < 1 year; Being in a dependent relationship with the trial site; Pregnancy or breast feeding women.